Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Analysts at HC Wainwright issued their FY2029 earnings estimates for Galectin Therapeutics in a research note issued to investors on Wednesday, April 2nd. HC Wainwright analyst E. Arce forecasts that the company will earn ($0.91) per share for the year. HC Wainwright has a "Neutral" rating on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share.
Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its earnings results on Monday, March 31st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.03).
Separately, StockNews.com lowered shares of Galectin Therapeutics from a "hold" rating to a "sell" rating in a report on Monday, December 30th.
Read Our Latest Research Report on GALT
Galectin Therapeutics Stock Performance
GALT stock traded up $0.01 during mid-day trading on Friday, hitting $1.33. 296,924 shares of the company were exchanged, compared to its average volume of 323,557. Galectin Therapeutics has a 1-year low of $0.73 and a 1-year high of $4.27. The firm's 50 day simple moving average is $1.46 and its 200 day simple moving average is $1.92. The firm has a market cap of $83.71 million, a P/E ratio of -1.82 and a beta of 0.79.
Institutional Trading of Galectin Therapeutics
A number of institutional investors have recently made changes to their positions in GALT. PNC Financial Services Group Inc. acquired a new stake in Galectin Therapeutics in the 4th quarter valued at $26,000. Inspire Advisors LLC grew its stake in Galectin Therapeutics by 86.3% in the fourth quarter. Inspire Advisors LLC now owns 21,095 shares of the company's stock valued at $27,000 after purchasing an additional 9,772 shares in the last quarter. HighTower Advisors LLC bought a new stake in shares of Galectin Therapeutics during the 4th quarter worth approximately $29,000. Two Sigma Securities LLC acquired a new stake in shares of Galectin Therapeutics in the 4th quarter valued at approximately $37,000. Finally, Bank of America Corp DE grew its stake in shares of Galectin Therapeutics by 101.4% in the fourth quarter. Bank of America Corp DE now owns 38,358 shares of the company's stock valued at $49,000 after buying an additional 19,316 shares in the last quarter. Institutional investors own 11.68% of the company's stock.
About Galectin Therapeutics
(
Get Free Report)
Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.
Featured Stories
Before you consider Galectin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.
While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
